Innovative Therapieansätze bei Tumoren des Magens und des Ösophagus

Gastric cancer represents the fifth common malignant disease worldwide and one of the most frequent causes of tumor related deaths. Despite the development of multimodal therapeutic approaches and the integration of novel therapeutic agents, prognosis remains poor with an estimated 5-year survival rate in metastatic disease of less than 20 %. Perioperative chemotherapy plus surgery has become the recommended standard treatment for patients with locally advanced, resectable gastric cancer and adenocarcinoma of the gastroesophageal junction. For those patients with advanced inoperable or metastatic disease palliative chemotherapy remains the standard of care. Recently published data and ongoing studies underline the potential of novel therapeutic agents such as immuncheckpoint inhibitors in the treatment of gastric cancer. This review summarizes the available evidence and discusses novel therapeutic approaches for patients with gastric cancer.